gvtcx

NP47825 Multiple Sclerosis Medicines

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£51,517,832
Statuscomplete
Category (CPV) 33600000
RegionScotland
Deadline7 Feb 2025
Procedureopen
OCIDocds-h6vhtk-04ce06

Awards (8)

This procurement was awarded to 8 suppliers. Values shown are per-award; the notice total is £51,517,832.

SupplierValueDateStatus
Biogen Idec Ltd shared · · ·
Merck Serono Limited shared · · ·
Orifarm UK shared · · active
Ranbaxy (UK) Ltd shared · · ·
Sandoz Ltd shared · · active
STADA UK - Thornton & Ross shared · · active
Teva UK Ltd shared · · ·
Viatris UK Healthcare Ltd shared · · active

description

Supply of multiple sclerosis medicines to NHS Scotland.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

3 notices published against this procurement.

PublishedTypeRegimeNotice
7 Jan 2025 Contract notice (F02) Earlier regulations 000410-2025
8 Jan 2025 Corrigendum (F14) Earlier regulations 000437-2025
2 May 2025 Contract award notice (F03) Earlier regulations 018635-2025

more from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.